These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
206 related items for PubMed ID: 13664785
1. The maintenance of a sustained thrombolytic state in man. I. Induction and effects. FLETCHER AP, ALKJAERSIG N, SHERRY S. J Clin Invest; 1959 Jul; 38(7):1096-110. PubMed ID: 13664785 [No Abstract] [Full Text] [Related]
2. The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. FLETCHER AP, SHERRY S, ALKJAERSIG N, SMYRNIOTIS FE, JICK S. J Clin Invest; 1959 Jul; 38(7):1111-9. PubMed ID: 13664786 [No Abstract] [Full Text] [Related]
3. Developments in fibrinolytic therapy for thrombo-embolic disease. SHERRY S, FLETCHER AP, ALKJAERSIG N. Ann Intern Med; 1959 Mar; 50(3):560-70. PubMed ID: 13627713 [No Abstract] [Full Text] [Related]
4. [On the dosage of streptokinase in fibrinolytic therapy]. STACHER A, BOEHNEL J. Wien Klin Wochenschr; 1961 Sep 29; 73():665-8. PubMed ID: 13916043 [No Abstract] [Full Text] [Related]
10. EXPERIENCE WITH STREPTOKINASE AS A THROMBOLYTIC AGENT. WINCKELMANN G, HIEMEYER V. Scand J Clin Lab Invest; 1964 Nov 29; 16():SUPPL 79:7-14. PubMed ID: 14199708 [No Abstract] [Full Text] [Related]
11. THE DEVELOPMENT OF UROKINASE AS A THROMBOLYTIC AGENT. MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN BY ITS INTRAVENOUS INFUSION. FLETCHER AP, ALKJAERSIG N, SHERRY S, GENTON E, HIRSH J, BACHMANN F. J Lab Clin Med; 1965 May 29; 65():713-31. PubMed ID: 14281368 [No Abstract] [Full Text] [Related]
12. The problem of therapy with fibrinolytic substances. FLETCHER AP. Proc R Soc Med; 1952 Aug 29; 45(8):499-500. PubMed ID: 12993801 [No Abstract] [Full Text] [Related]
13. [Streptokinase-streptodornase; its fibrinolytic and liquefying action on purulent exudates and approval for therapy of suppurations]. ELIAS COSTA JD. Sem Med; 1953 Jan 15; 102(3):77-82. PubMed ID: 13056691 [No Abstract] [Full Text] [Related]
14. [LIMITATIONS OF USE AND HAZARDS OF FIBRINOLYTIC THERAPY WITH STREPTOKINASE]. OHLER WG. Med Klin; 1964 Jan 10; 59():61-4. PubMed ID: 14134684 [No Abstract] [Full Text] [Related]
15. [Note on the value of fibrinolytic enzymes in the evolution of extra and intrapleural pneumothorax]. CATTA J, SOURNIA JC. Presse Med (1893); 1952 Jul 19; 60(49):1061-2. PubMed ID: 13026890 [No Abstract] [Full Text] [Related]
16. Assay of thrombolytic ('fibrinolytic') mixtures intended for therapeutic use. FLETCHER AP, ALKJAERSIG N, SHERRY S. J Lab Clin Med; 1961 Apr 19; 57():620-9. PubMed ID: 13700257 [No Abstract] [Full Text] [Related]
17. [Advantages of fibrinolytic enzymes in thoracic surgery]. RAZEMON P, RIBET M. Lille Chir; 1952 Apr 19; 7(37):53-61. PubMed ID: 14956066 [No Abstract] [Full Text] [Related]
20. [Variations in the clinical and fluid aspects in patients with tuberculous meningitis exposed to intraspinal fibrinolytic therapy]. QUARATO B. Prog Med (Napoli); 1955 Nov 15; 11(21):644-50. PubMed ID: 13297839 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]